Transcenta Holding Limited (6628) AI Stock Analysis

• Market Cap: HK$1.35B
• Dividend Yield: N/A
• Average Volume (3M): 3.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -57.84%
• EPS Growth: 24.58%
• Country: HK
• Employees: 184
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 452,075,500
• 10 Day Avg. Volume: 1,978,041
• 30 Day Avg. Volume: 3,470,422
• PEG Ratio: 0.02
• Price to Book (P/B): 0.32
• Price to Sales (P/S): 21.27
• P/FCF Ratio: -1.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: HK$3.00 ▼(-15.97% Downside)

The overall stock score is primarily driven by significant financial challenges and a concerning valuation. Technical analysis indicates bearish momentum, further impacting the score. The absence of earnings call data and corporate events means these factors do not influence the score.

Transcenta Holding Limited Business Overview & Revenue Model

Company Description

Transcenta Holding Limited (6628) is a biopharmaceutical company focused on the discovery, development, and manufacturing of innovative therapeutics. The company operates primarily in the healthcare sector, with a core emphasis on antibody-based biologics. Transcenta's portfolio includes a pipeline of proprietary biologic candidates targeting cancer, bone and kidney diseases, and other serious medical conditions.

How the Company Makes Money

Transcenta makes money through the development and commercialization of its biologic drug candidates. The company's revenue model is primarily based on partnerships and collaborations with other pharmaceutical companies, where they may receive milestone payments, royalties, and licensing fees for the rights to develop and market their drug candidates. Additionally, Transcenta invests in manufacturing capabilities to support its pipeline, which can also generate revenue through contract manufacturing services offered to other biotech companies. Significant partnerships with global pharmaceutical firms enhance Transcenta's capabilities in research and development, providing a steady flow of income through strategic collaborations.

Transcenta Holding Limited Financial Statement Overview

Summary

Transcenta Holding Limited faces significant financial challenges, with negative margins, declining revenues, high leverage, negative returns, and severe cash flow distress. The company requires strategic restructuring or additional capital.

Income Statement

The income statement reveals significant challenges for Transcenta Holding Limited. The company has experienced a declining revenue trend, with a notable drop from 2022 to 2023. Gross profit margin has decreased significantly, indicating rising costs or pricing pressures. Net profit margins are negative due to substantial net losses, reflecting ongoing financial struggles. Both EBIT and EBITDA margins are deeply negative, underscoring poor operational performance.

Balance Sheet

The balance sheet shows moderate financial health with some areas of concern. The debt-to-equity ratio is relatively high, indicating significant leverage. However, the equity ratio is positive, suggesting a stable asset base. Return on equity is negative due to net losses. Overall, the balance sheet reflects potential risk from high debt levels but also indicates some strength in asset management.

Cash Flow

Cash flow analysis indicates severe financial distress. The company reports zero or negative free cash flows across recent periods, highlighting a lack of cash generation capability. The operating cash flow to net income ratio is unfavorable, and free cash flow growth rate is negative, illustrating ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.41M	11.26M	53.85M	101.89M	50.24M	80.98M
Gross Profit	3.27M	4.00M	14.40M	19.89M	9.37M	18.20M
EBITDA	-211.90M	-233.12M	-393.01M	-334.09M	-1.65B	-264.81M
Net Income	-266.36M	-290.29M	-462.57M	-406.75M	-1.72B	-316.63M
Balance Sheet
Total Assets	1.04B	1.20B	1.69B	2.13B	2.54B	2.09B
Cash, Cash Equivalents and Short-Term Investments	45.81M	169.42M	546.03M	895.45M	1.22B	813.59M
Total Debt	210.14M	250.61M	409.63M	411.46M	364.71M	254.30M
Total Liabilities	386.57M	448.64M	665.67M	660.64M	579.39M	2.91B
Stockholders Equity	652.13M	751.64M	1.03B	1.47B	1.97B	-816.25M
Cash Flow
Free Cash Flow	-175.14M	-216.15M	-373.80M	-318.03M	-457.84M	-237.73M
Operating Cash Flow	-170.07M	-213.83M	-358.04M	-295.81M	-384.50M	-174.40M
Investing Cash Flow	8.23M	14.28M	57.47M	-102.61M	-69.77M	-57.74M
Financing Cash Flow	-157.75M	-178.06M	-47.20M	26.72M	879.71M	620.17M

Transcenta Holding Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 4.09, and above the 200-day MA of 2.20, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 37.90 is Neutral, neither overbought nor oversold. The STOCH value of 19.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6628.

Transcenta Holding Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	―	HK$1.54B	189.52	0.99%	―	9.41%	-32.69%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2197	―	HK$2.67B	-2.57	―	―	79.98%	-3.40%
2257	―	HK$1.05B	―	―	―	―	83.89%
3681	―	HK$2.24B	―	-55.33%	―	-100.00%	30.68%
6628	―	HK$1.35B	-4.32	-34.18%	―	-57.84%	24.58%
9939	―	HK$921.92M	―	-54.87%	―	―	81.67%

Transcenta Holding Limited Corporate Events

Transcenta Advances Financial and Strategic Initiatives to Strengthen Position

Transcenta Holding Limited has made significant progress in addressing the disclaimer of opinion in its 2024 annual report by implementing key measures to strengthen its financial position and enhance liquidity. The company is actively engaging with global and regional partners for the development and commercialization of its major pipeline assets, pursuing out-licensing and fundraising opportunities, and exploring innovative financing models to support its research and development efforts. These actions are expected to improve the company’s operational capabilities and strategic positioning in the biotechnology industry.

The most recent analyst rating on (HK:6628) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.

Transcenta Explores Blockchain-Based Financing for Oncology Innovations

Transcenta Holding Limited has announced a strategic collaboration with IVD Medical Holding Limited and its subsidiaries to explore the issuance of Real-World Asset Tokens on the Ethereum blockchain. This innovative financing strategy, enabled by regulatory reforms in the U.S. and China, aims to fund the accelerated development of several oncology treatments, potentially democratizing investment opportunities in biotechnology and enhancing the company’s industry positioning.

The most recent analyst rating on (HK:6628) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.

Transcenta Completes HK$59.34 Million Share Placement

Transcenta Holding Limited has successfully completed the placement of 14,400,000 new shares under a general mandate, raising approximately HK$59.34 million. This strategic move, facilitated by BOCI Asia Limited, aims to strengthen the company’s financial position and potentially enhance its market presence, with the new shares being issued to independent third-party investors.

The most recent analyst rating on (HK:6628) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.

Transcenta Holding Limited Announces New Share Placement to Raise HK$59.34 Million

Transcenta Holding Limited has announced a new share placement under a general mandate, involving the issuance of 14,400,000 shares, representing about 3.31% of the current total shares. The placement, coordinated by BOCI Asia Limited, is priced at a discount to recent market prices, aiming to raise approximately HK$59.34 million in net proceeds. This strategic move is intended to strengthen the company’s financial position and support its operational goals, although completion is contingent on certain conditions being met.

The most recent analyst rating on (HK:6628) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.

Transcenta Reports Interim Results with Strategic Adjustments

Transcenta Holding Limited announced its interim results for the six months ended June 30, 2025, revealing a decrease in revenue primarily due to a decline in CDMO services. Despite this, the company saw an increase in other income from government subsidies and a reduction in research and development expenses, which contributed to a decrease in overall losses. The company’s strategic reprioritization of resources and pipeline advancement efforts were highlighted as key factors in the financial performance during this period.

The most recent analyst rating on (HK:6628) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.

Transcenta Holding Limited Schedules Board Meeting to Review Interim Results

Transcenta Holding Limited has announced a board meeting scheduled for August 27, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, indicating a potential return to shareholders and reflecting on the company’s financial health and strategic direction.